Ocuphire still focused on FDA approval despite diabetic eye drug missing phase 2 endpoint

Ocuphire Pharma’s diabetic retinopathy (DR) candidate missed the primary endpoint of a phase 2 trial, sending the company’s shares down over 25%. But the biotech has suggested that the drug’s effect on both eyes could still offer a path to FDA approval.